BACKGROUND: Increased bilirubin production due to hemolysis can lead to neonatal hyperbilirubinemia. Inhibition of heme oxygenase (HO), the rate-limiting enzyme in heme catabolism, by metalloporphyrins (Mps) may be an ideal preventive strategy for neonatal hemolytic disease. Zinc protoporphyrin (ZnPP) is a naturally occurring Mp, potent, not phototoxic, with minimal HO-1 upregulation, but is not orally absorbed. Recently, we designed a lipid-based ZnPP formulation (ZnPP-Lipid), which is orally absorbed by newborn mice. Here, we evaluated the efficacy of ZnPP-Lipid in heme-loaded newborn mice, a model analogous to hemolytic infants. METHODS: After 24 h of heme administration (30 µmol/kg s.c.), 4-d-old mice were given 30 µmol ZnPP-Lipid/kg via intragastric injections. After 3 h, liver and brain HO activity were measured. HO-1 upregulation was assessed by determinations of HO-1 protein, promoter activity, and mRNA by Western blot, in vivo bioluminescence imaging, and RT-PCR, respectively. RESULTS: After heme loading, liver HO activity significantly increased ~1.6-fold, which was inhibited in a dose-dependent manner by ZnPP-Lipid. A dose of 30 µmol/kg returned activity to control levels. Brain HO activity was not inhibited. No significant increases in liver and brain HO-1 protein, promoter activity, and mRNA were observed. CONCLUSION: ZnPP-Lipid is effective and thus has potential for treating neonatal hyperbilirubinemia due to hemolysis.
BACKGROUND: Increased bilirubin production due to hemolysis can lead to neonatal hyperbilirubinemia. Inhibition of heme oxygenase (HO), the rate-limiting enzyme in heme catabolism, by metalloporphyrins (Mps) may be an ideal preventive strategy for neonatal hemolytic disease. Zinc protoporphyrin (ZnPP) is a naturally occurring Mp, potent, not phototoxic, with minimal HO-1 upregulation, but is not orally absorbed. Recently, we designed a lipid-based ZnPP formulation (ZnPP-Lipid), which is orally absorbed by newborn mice. Here, we evaluated the efficacy of ZnPP-Lipid in heme-loaded newborn mice, a model analogous to hemolytic infants. METHODS: After 24 h of heme administration (30 µmol/kg s.c.), 4-d-old mice were given 30 µmol ZnPP-Lipid/kg via intragastric injections. After 3 h, liver and brain HO activity were measured. HO-1 upregulation was assessed by determinations of HO-1 protein, promoter activity, and mRNA by Western blot, in vivo bioluminescence imaging, and RT-PCR, respectively. RESULTS: After heme loading, liver HO activity significantly increased ~1.6-fold, which was inhibited in a dose-dependent manner by ZnPP-Lipid. A dose of 30 µmol/kg returned activity to control levels. Brain HO activity was not inhibited. No significant increases in liver and brain HO-1 protein, promoter activity, and mRNA were observed. CONCLUSION:ZnPP-Lipid is effective and thus has potential for treating neonatal hyperbilirubinemia due to hemolysis.
Authors: Ichiro Morioka; Ronald J Wong; Aida Abate; Hendrik J Vreman; Christopher H Contag; David K Stevenson Journal: Pediatr Res Date: 2006-05 Impact factor: 3.756
Authors: S D Appleton; M L Chretien; B E McLaughlin; H J Vreman; D K Stevenson; J F Brien; K Nakatsu; D H Maurice; G S Marks Journal: Drug Metab Dispos Date: 1999-10 Impact factor: 3.922
Authors: Cynthia X He; Claire M Campbell; Hui Zhao; Flora S Kalish; Stephanie Schulz; Hendrik J Vreman; Ronald J Wong; David K Stevenson Journal: Pediatr Res Date: 2011-11 Impact factor: 3.756
Authors: Brenda H Morris; William Oh; Jon E Tyson; David K Stevenson; Dale L Phelps; T Michael O'Shea; Georgia E McDavid; Rebecca L Perritt; Krisa P Van Meurs; Betty R Vohr; Cathy Grisby; Qing Yao; Claudia Pedroza; Abhik Das; W Kenneth Poole; Waldemar A Carlo; Shahnaz Duara; Abbot R Laptook; Walid A Salhab; Seetha Shankaran; Brenda B Poindexter; Avroy A Fanaroff; Michele C Walsh; Maynard R Rasmussen; Barbara J Stoll; C Michael Cotten; Edward F Donovan; Richard A Ehrenkranz; Ronnie Guillet; Rosemary D Higgins Journal: N Engl J Med Date: 2008-10-30 Impact factor: 91.245
Authors: Stephanie Schulz; Ronald J Wong; Flora S Kalish; Hui Zhao; Kyu Yun Jang; Hendrik J Vreman; David K Stevenson Journal: Pediatr Res Date: 2012-08 Impact factor: 3.756
Authors: Susan E Wiedmeier; Timothy M Bahr; Robin K Ohls; Thomas R Christensen; Vickie L Baer; Sarah J Ilstrup; Kelly Cail; Robert D Christensen Journal: J Perinatol Date: 2020-07-15 Impact factor: 2.521